Pasithea Q3 Loss Widens to $6.6M as R&D Spend Triples; $41.2M Cash Remains
KTTA sits 70% above its 52-week low of $0.281 on elevated volume (3.6× avg).
Summary
Pasithea's Q3 2026 net loss widened to $6.58 million as R&D spending more than tripled, leaving $41.2 million in cash that management says funds at least 12 months of operations.
Key Events · Earnings and Guidance · KTTA
-
Q3 Loss Widens on R&D Ramp
The net loss came to $6,579,393 for the three months ended September 30, 2026, versus $3,037,420 a year earlier; for the nine months, the loss was $14,722,727 versus $10,316,815.
-
R&D Spending More Than Triples
Research and development rose 228.3% to $4,457,107 in Q3 2026, driven by $2,570,000 of higher clinical trial and regulatory costs; G&A rose 43.4% to $2,512,575.
-
Cash Falls but Runway Affirmed
Cash and equivalents stood at $41,218,508 at September 30, 2026, down from $55,158,939 at December 31, 2025; management concluded there is no substantial doubt about going concern and that funding covers at least 12 months.
-
Share Count Climbs on Warrant Exercises
Shares outstanding reached 33,414,448 at September 30, 2026 versus 23,091,062 at year-end 2025; 10,324,500 pre-funded warrants were exercised in the nine months and 3,338,100 more between October 1 and November 12, 2026, with 51,490,735 pre-funded warrants still outstanding.
Analysis · KTTA · Life Sciences
A sharply wider quarterly loss reflects Pasithea's ramp-up on PAS-004, the MEK inhibitor that just delivered its first efficacy data in NF1 patients. Research and development jumped 228.3% to $4.46 million in the quarter, driving a $6.58 million net loss versus $3.04 million a year earlier. The offsetting positive sits on the balance sheet: $41.2 million of cash and equivalents at September 30, down from $55.2 million at year-end 2025, with management stating it has no substantial doubt about going concern and enough funding for at least 12 months. That runway matters because the company is now funding a Phase 2 cNF trial cleared by the FDA in November 2026 alongside the ongoing Phase 1/1b PN study. Dilution is already embedded: 33.4 million shares outstanding at quarter-end versus 23.1 million at December 31, 2025, plus 51.5 million pre-funded warrants still exercisable at $0.001, and 3.34 million more exercised since quarter-end.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KTTA was trading at $0.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.4M. The 52-week trading range was $0.28 to $2.06. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.